JP7805170B2 - 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 - Google Patents

前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Info

Publication number
JP7805170B2
JP7805170B2 JP2021578240A JP2021578240A JP7805170B2 JP 7805170 B2 JP7805170 B2 JP 7805170B2 JP 2021578240 A JP2021578240 A JP 2021578240A JP 2021578240 A JP2021578240 A JP 2021578240A JP 7805170 B2 JP7805170 B2 JP 7805170B2
Authority
JP
Japan
Prior art keywords
compound
formula
psma
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021578240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538478A (ja
Inventor
エフ． マリアニ，マウリツィオ
フガッツァ，ロレンツァ
キッコ，ダニエラ
ギルバート ポンパー，マーティン
レイ，サンギータ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2022538478A publication Critical patent/JP2022538478A/ja
Priority to JP2025120662A priority Critical patent/JP2025165975A/ja
Application granted granted Critical
Publication of JP7805170B2 publication Critical patent/JP7805170B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021578240A 2019-07-02 2020-06-30 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用 Active JP7805170B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120662A JP2025165975A (ja) 2019-07-02 2025-07-17 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19184015.6 2019-07-02
EP19184015 2019-07-02
PCT/EP2020/068386 WO2021001360A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120662A Division JP2025165975A (ja) 2019-07-02 2025-07-17 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Publications (2)

Publication Number Publication Date
JP2022538478A JP2022538478A (ja) 2022-09-02
JP7805170B2 true JP7805170B2 (ja) 2026-01-23

Family

ID=67145647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021578240A Active JP7805170B2 (ja) 2019-07-02 2020-06-30 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
JP2025120662A Pending JP2025165975A (ja) 2019-07-02 2025-07-17 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120662A Pending JP2025165975A (ja) 2019-07-02 2025-07-17 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用

Country Status (16)

Country Link
US (1) US20230226227A1 (https=)
EP (1) EP3993837A1 (https=)
JP (2) JP7805170B2 (https=)
KR (1) KR20220044496A (https=)
CN (3) CN120441497A (https=)
AR (1) AR119331A1 (https=)
AU (3) AU2020299974A1 (https=)
BR (1) BR112021026812A2 (https=)
CA (1) CA3144557A1 (https=)
CL (1) CL2021003525A1 (https=)
CO (1) CO2021017708A2 (https=)
IL (1) IL289039B1 (https=)
MX (1) MX2022000136A (https=)
PH (1) PH12021553284A1 (https=)
TW (1) TW202114742A (https=)
WO (1) WO2021001360A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230330278A1 (en) * 2020-04-29 2023-10-19 Novartis Ag Methods for radiolabelling psma binding ligands and their kits
KR20260040237A (ko) 2023-07-21 2026-03-24 노파르티스 아게 Psma 표적 방사성 리간드 치료 요법
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222778A1 (en) 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271026A1 (en) 2000-07-11 2002-01-21 Bml, Inc. Remedies for bone diseases
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
LT4095130T (lt) * 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
HRP20240215T1 (hr) * 2016-03-22 2024-04-26 The Johns Hopkins University Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate
KR20250126870A (ko) * 2018-02-06 2025-08-25 더 존스 홉킨스 유니버시티 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트
WO2020028323A1 (en) * 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222778A1 (en) 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

Also Published As

Publication number Publication date
US20230226227A1 (en) 2023-07-20
AU2024200850B2 (en) 2025-09-04
CN120441497A (zh) 2025-08-08
TW202114742A (zh) 2021-04-16
PH12021553284A1 (en) 2022-08-01
AU2024200850A1 (en) 2024-02-29
JP2022538478A (ja) 2022-09-02
BR112021026812A2 (pt) 2022-02-22
JP2025165975A (ja) 2025-11-05
CN120441498A (zh) 2025-08-08
IL289039B1 (en) 2026-03-01
AU2025271182A1 (en) 2025-12-18
IL289039A (en) 2022-02-01
CL2021003525A1 (es) 2022-10-21
CA3144557A1 (en) 2021-01-07
CN114341118A (zh) 2022-04-12
KR20220044496A (ko) 2022-04-08
MX2022000136A (es) 2022-04-27
EP3993837A1 (en) 2022-05-11
AU2020299974A1 (en) 2022-01-27
AR119331A1 (es) 2021-12-09
CO2021017708A2 (es) 2022-05-20
WO2021001360A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
JP6556805B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
CN111285918B (zh) 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
JP2025165975A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
JP2022518956A (ja) がん診断用画像化剤
IL194826A (en) Compounds 4n are conjugated to a target ligand and a kit containing it
JP2022513630A (ja) 治療および画像化のためのデンドリマー
JP2024500829A (ja) 治療診断剤として使用するための放射性標識α－Ｖβ－３及び／又はα－Ｖβ－５インテグリンアンタゴニスト
JP7608378B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
CN119874628B (zh) 一种含氮化合物及其制备方法与用途
HK1123306B (en) Compositions and methods for cellular imaging and therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230623

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260113

R150 Certificate of patent or registration of utility model

Ref document number: 7805170

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150